Updated 21 October 2026.
The UK government's decision to continue recognising CE-marked medical devices changes the planning environment for clinical AI. It does not remove the MHRA, make every medical chatbot lawful, or turn a conformity mark into an NHS purchasing decision. The consequential change is narrower and more useful: manufacturers should no longer have to plan around an eventual compulsory switch to a separate British conformity-assessment route simply to retain Great Britain market access.
The 21 October announcement confirms the policy direction. The accompanying consultation outcome says legislative changes will follow. That distinction matters: this is a confirmed government decision to implement indefinite recognition, not evidence that every implementing amendment has already commenced.
What is being recognised indefinitely?
The intended permanent recognition covers devices complying with the EU Medical Device Regulation, or EU MDR, and the EU In Vitro Diagnostic Medical Devices Regulation, or EU IVDR. The government also plans to align transitional arrangements for older EU Medical Devices Directive devices with the relevant EU transition. It is not granting permanent validity to every historic CE certificate. The full response separates those issues explicitly.
A manufacturer must therefore identify the legislation supporting its product, the applicable transitional conditions and the continuing validity of its conformity documentation. The word "indefinite" describes recognition of a route, not an exemption from maintaining conformity, responding to safety issues or controlling product changes.
The territorial distinction is equally important. The announcement concerns Great Britain: England, Scotland and Wales. Northern Ireland has its own applicable arrangements linked to EU device rules. Using "UK" in a headline should not erase that operational difference.
CE marking is not an alternative to MHRA registration
Conformity assessment and device registration answer different questions. The former concerns whether a device meets the requirements for its intended purpose and regulatory route. The latter makes the manufacturer and device known to the relevant authority. Recognition of a CE route does not make the registration requirement disappear.
The MHRA's registration guidance remains the practical starting point for Great Britain. Manufacturers also need to address the UK Responsible Person requirement where applicable and continue meeting domestic surveillance obligations. A purchaser should consequently ask for the exact product, manufacturer, intended purpose, territory and registration position, rather than accept a general statement that a company is "European approved".
This also corrects a frequent marketing shortcut. Registration is not a personal endorsement by the MHRA of every answer a clinical AI system produces. Equally, a conformity mark is meaningful without being a guarantee of comparative superiority.
Why clinical AI developers should care
Consider a fictional company developing software to support a defined clinical decision. It expects to sell in several European countries and Britain. Under a model in which British recognition expires, the company must reserve resources for another route even when its European conformity work remains valid. That additional uncertainty can affect sequencing, investment and whether a relatively small market receives an early launch.
Long-term recognition can reduce that duplication risk. The important word is "can": the company still needs a compliant product, evidence, implementation capability and customers. A regulatory announcement does not substitute for any of them.
The competitive consequence is that the certification decision becomes less entangled with an artificial market-access deadline. Developers can devote more attention to the difficult questions that remain: which clinical function to build, what evidence to generate, and how to deploy it reliably.
The policy is nationality-neutral
It is tempting to describe the decision as a gift exclusively to EU-headquartered companies. That is too simple. A British manufacturer or an American company with qualifying CE-marked products can also benefit from recognition. The relevant characteristic is the product's regulatory route, not the passport of its founders.
Nevertheless, an established European clinical AI supplier may be well positioned to exploit the change when it already has conformity-assessment experience, local implementation teams and British distribution relationships. Those are commercial advantages that can compound. They are not proof that the underlying model is more accurate.
For smaller British businesses, the response should not be to abandon specialisation. A stronger strategy may be to demonstrate exceptional performance in a clearly defined task, with evidence and local relevance that a broad platform cannot establish merely through scale.
Why the NHS remains a separate hurdle
A device can have an acceptable route to market and still be unsuitable for a particular service. The local system may lack an integration, clinicians may need more review time than expected, or the evidence may not represent the intended population. These are deployment questions, not contradictions of regulatory recognition.
NHS DTAC guidance provides an assurance framework covering digital products, while clinical risk management standards address responsibilities around development and deployment. Procurement teams also need a credible account of costs, training, incident handling and service continuity.
An organisation evaluating AI should therefore run two assessments in parallel. One establishes the lawful and documented product scope. The other tests whether the proposed workflow is beneficial, safe and practical locally. Neither assessment can simply borrow the other's conclusion.
Adaptive software still needs continuing scrutiny
The question does not end when software enters the market. A model replacement, revised retrieval system or change to a clinical protocol may alter behaviour without changing the product's name. Buyers need version information and a meaningful explanation of how updates are assessed.
The government's response to the National Commission on AI regulation addresses a wider reform programme. Those plans should not be confused with the separate CE-recognition decision. International recognition can reduce duplicated entry requirements; it cannot, by itself, solve monitoring, change control or accountability for evolving AI systems.
This is where a productive British regulatory strategy could distinguish itself: make entry proportionate while improving the visibility of what happens after deployment. Less duplication and stronger oversight are not inherently opposing objectives.
What this means for clinicians and iatroX
For clinicians, the immediate practical lesson is to become more precise about product claims. Ask what the software does, what evidence supports that function and which information remains your responsibility to check. Do not use a badge as a shortcut for assessing a recommendation's relevance.
For iatroX, the competitive opportunity remains clinical knowledge and learning rather than pretending to replace every part of the clinical software stack. Ask-iatroX provides an independently accessible reference workflow, while Socratic Tutor and simulations address learning tasks. These functions should be judged on their own purposes, not on assumptions about another supplier's certification.
The policy creates a more predictable market. The companies that turn that predictability into useful, inspectable and locally relevant products will have the stronger claim on clinicians' attention.
Frequently asked questions
Does a CE mark now replace MHRA registration?
No. The announced recognition policy concerns conformity-assessment routes. The consultation response expressly preserves applicable domestic obligations, including MHRA registration, UK Responsible Person arrangements and post-market surveillance.
Are the changes already fully implemented in legislation?
The government confirmed its decision on 21 October 2026 and said it would proceed with legislative changes. Manufacturers should distinguish that decision from the commencement of the implementing requirements.
Does the decision make a CE-marked AI tool NHS approved?
No. Market access, local clinical safety assurance, information governance, procurement and evidence of benefit are separate questions. The organisation must assess the actual product and proposed use.
Keep the clinical question in view
Explore Ask-iatroX for source-linked clinical reference alongside the regulatory and workflow checks your service requires.